You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Demographic and clinical characteristics stratified by infection outcomes in the intent to treat study population

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

  No infection N = 501 (98.2%) Infection N = 9 (1.8%) All N = 510 P value
Demographics
 Age, mean +/− SD, (range), years 62.5 ± 8.9 (33–88) 63.4 ± 6.5 (48–71) 62.5 ± 8.9 (33–88) 0.75
 Race, n (%)     1.0
  White 368 (73.5) 8 (88.9) 376 (73.7)  
  Black 82 (16.4) 1 (11.1) 83 (16.3)  
  Hispanic 30 (6.0) 0 (0.0) 30 (5.9)  
  Other 21 (4.2) 0 (0.0) 21 (4.1)  
Clinical characteristics
 Biopsy result, n (%)     0.611
  Negative 253 (50.5) 4 (44.4) 257 (50.4)  
  Prostate cancer 196 (39.1) 5 (55.6) 201 (39.4)  
  HGPIN 52 (10.4) 0 (0.0) 52 (10.2)  
 History of urinary tract infection, n (%)     0.029
  Yes 52 (10.4) 3 (33.3) 55 (10.8)  
  No 437 (87.2) 5 (55.6) 442 (86.7)  
  Unknown/missing 12 (2.4) 1 (11.1) 13 (2.5)  
 History of urinary retention; n (%)     0.499
  Yes 38 (7.6) 1 (11.1) 39 (7.6)  
  No 410 (81.8) 8 (88.9) 418 (82.0)  
  Unknown/missing 53 (10.6) 0 (0.0) 53 (10.4)  
 FQ usage in prior 2 years, n (%)     0.678
  Yes 111 (22.2) 3 (33.3) 114 (22.3)  
  No 263 (52.5) 4 (44.4) 267 (52.4)  
  Unknown/missing 127 (25.3) 2 (22.2) 129 (25.3)  
 Hospitalized in prior 1 year; n (%)     0.400
  Yes 46 (9.2) 2 (22.2) 48 (9.4)  
  No 440 (87.8) 7 (77.8) 447 (87.7)  
  Unknown/missing 15 (3.0) 0 (0.0) 15 (2.9)  
 Healthcare worker; n (%)     0.713
  Yes 16 (3.2) 0 (0.0) 16 (3.1)  
  No 418 (83.4) 9 (100) 427 (83.7)  
  Unknown/missing 67 (13.4) 0 (0.0) 67 (13.1)  
 Charlson comorbidity score; n (%)     0.139
  0 410 (81.8) 6 (66.7) 416 (81.6)  
  1 17 (3.4) 1 (11.1) 18 (3.5)  
  2 35 (7.0) 0 (0.0) 35 (6.9)  
  3–16 39 (7.8) 2 (22.2) 41 (8.0)  
  1. Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, FQ fluoroquinolone